Engineered Bacterial Therapeutics: Controlled Release Approaches in Oncology

Area of Science:

• Biomedical Engineering
• Oncology
• Microbiology

Background:

• Engineered bacteria are emerging as potent tools in cancer therapy, demonstrating considerable clinical promise.
• Clinical application necessitates enhanced biosafety and precise tumor targeting for engineered bacterial therapeutics.
• Controlled release systems are crucial for optimizing engineered bacteria via spatiotemporal gene expression and motility regulation.

Purpose of the Study:

• To systematically review controlled release platforms for engineered bacteria in tumor treatment.
• To analyze tumor microenvironment-responsive and intelligent controllable systems.
• To provide a foundation for improving bacteria-mediated antitumor therapy.

Main Methods:

• Systematic evaluation of two primary controlled release platforms: tumor microenvironment-responsive and intelligent controllable systems.
• Summary of representative therapeutic strategies utilizing these platforms.
• Critical analysis of the advantages and disadvantages of each approach.

Main Results:

• Tumor microenvironment-responsive systems leverage specific tumor conditions for bacterial activation and drug delivery.
• Intelligent controllable systems offer external regulation of bacterial behavior and therapeutic payload release.
• Both platforms present distinct benefits and challenges impacting clinical translation.

Conclusions:

• Controlled release is pivotal for advancing engineered bacteria in oncology.
• Refining these systems will improve biosafety and therapeutic efficacy in bacteria-mediated antitumor strategies.
• Further research into optimized controlled release mechanisms is essential for clinical success.